info:eu-repo/semantics/article
Randomized trials addressing a similar question are commonly published after a trial stopped early for benefit
Fecha
2017Institución
Resumen
Objective: We explored how investigators of ongoing or planned trials respond to the publication of a trial stopped early for benefit addressing a similar question. Study Design and Setting: We searched multiple databases from the date of publication of the truncated trial through August, 2015. Independent reviewers selected trials and extracted data. Results: We identified 207 trials truncated for early benefit; of which 102 (49%) were followed by subsequent trials (262 subsequent trials, median 2 per truncated trial, range 1-13). Only 99 (38%) provided a rationale justifying conducting a trial despite prior stopping. The top reasons were to address different population or setting (33%), skepticism of truncated trials findings because of small sample size (12%), inconsistency with other evidence (11%), or increased risk of bias (7%). We did not identify significant associations between subsequent trials and characteristics of truncated ones (risk of bias, precision, funding, or rigor of stopping decision). Conclusion: About half of the trials stopped early for benefit were followed by subsequent trials addressing a similar question. This suggests that future trialists may have been skeptic about the decision to stop prior trials. A more rigorous threshold for stopping early for benefit is needed.
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
The effectiveness of antioxidant vitamins c and e in reducing myocardial infarct size in patients subjected to percutaneous coronary angioplasty (prevec trial): study protocol for a pilot randomized double-blind controlled trial
Rodrigo, Ramon; Hasson, Daniel; Prieto, Juan C.; Dussaillant, Gaston; Ramos, Cristobal; Leon, Lucio; Garate, Javier; Valls, Nicolas; Gormaz, Juan G. -
Randomized controlled trials for COVID-19: evaluation of optimal randomization methodologies - need for the data validation of the completed trials, and to improve the ongoing and future randomized trial designs
Emani, Venkata R.; Goswami, Sanjeev; Nandanoor, Dheeraj; Emani, Shaila R.; Reddy, Nidhi K.; Reddy, RaghunathCOVID-19. The Recovery trials showed an Absolute Risk Reduction (ARR) in mortality by 2.8% with Dexamethasone, and the ACTT-1 trial showed that the treatment with Remdesivir reduced the Time to recovery by 4 days. The ... -
Hemodynamic changes and quality of life in patients with prostate cancer after a HIIT and MICT training. A randomized clinical trial (ONCO-EXE TRIAL)
Pereira-Rodríguez, Javier Eliecer; Peñaranda-Florez, Devi Geesel; Pereira-Rodríguez, Ricardo; Pereira-Rodríguez, Pedro